

Applicant : Takuya Tamatani et al  
Serial No. : 09/383,551  
Filed : August 26, 1999  
Page : 23

Attorney's Docket No.: 06501-039001 / J1-802PCT-US

SVB  
H1  
211. A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:14, comprising providing a culture of the cell identified in claim 206, and collecting the antibody from the culture.

F8  
212. A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:14, comprising providing a culture of the cell identified in claim 207, and collecting the antibody from the culture.

213. A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:14, comprising providing a culture of the cell identified in claim 208, and collecting the antibody from the culture.

214. A process for producing an antibody that binds to a polypeptide consisting of SEQ ID NO:14, comprising providing a culture of the cell identified in claim 209, and collecting the antibody from the culture. u

In the abstract:

Replace the abstract with the following version.

F9  
A cell surface molecule that is expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes. This molecule is involved in signal transmission of the secondary signal (costimulatory signal) essential for the activation of lymphocytes such as T cells and regulates functions of activated lymphocytes such as activated T cells. Disclosed are an antibody or a portion thereof, which binds to a polypeptide of the cell surface molecule, a polypeptide fragment thereof, or a fusion polypeptide comprising the fragment; a cell secreting the antibody or its portion; a pharmaceutical composition comprising the antibody; and methods of using the compositions for therapeutic, diagnostic and/or experimental purpose. a